Posted on 1/29/21
Neuronetics Prices of $75 Million Public Offering of Common Stock
MALVERN, Pa., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that . . .
Posted on 1/29/21
Neuronetics Proposes Public Offering of Common Stock
MALVERN, Pa., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that . . .
Posted on 1/28/21
Helius Medical Technologies Prices of $9.6 Million Underwritten Public Offering
NEWTOWN, Pa., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM), a neurotech company focused on neurological wellness, announced today announced the pricing . . .
Posted on 1/28/21
Ortho Clinical Diagnostics Prices IPO
Ortho Clinical Diagnostics Holdings plc, the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, . . .
Posted on 1/27/21
Citius Pharmaceuticals Closes of $20.0 Million Private Placement
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has closed on the . . .
Posted on 1/27/21
Comcast Ties Up With WWE in Peacock Streaming Deal
Comcast (NASDAQ:CMCSA) is pushing its Peacock streaming video service into the wrestling ring. The big broadcaster has signed a multi-year deal with World Wrestling Entertainment (NYSE:WWE) . . .
Posted on 1/27/21
Why Pfizer Will Make More Money Than Originally Expected in 2021
We've all known for quite a while that Pfizer (NYSE:PFE) was likely to make billions of dollars from its COVID-19 vaccine. Granted, the big drugmaker has . . .
Posted on 1/27/21
Should You Buy Johnson & Johnson Stock Before Its Big Coronavirus Vaccine News?
The biggest healthcare company in the world has some really big news on the way. Johnson & Johnson (NYSE:JNJ) should announce results from a late-stage study . . .
Posted on 1/27/21
Is Pfizer A Great Dividend Stock?
Companies have a limited number of choices when deciding what to do with the money they earn. For mature businesses with relatively predictable earnings, a portion . . .
Posted on 1/27/21
Here's Why Investors Cheered Johnson & Johnson's Q4 Results
Johnson & Johnson (NYSE:JNJ) delivered a return of nearly 8% in 2020. Adding in the company's dividend gives a total return of close to 11%. That's . . .
Posted on 1/27/21
Johnson & Johnson Rises on Q4 Beats, Coronavirus Vaccine Hopes
Johnson & Johnson (NYSE:JNJ) delivered an encouraging set of quarterly results on Tuesday, which included a promising -- albeit limited -- update on its coronavirus vaccine . . .
Posted on 1/26/21
Johnson & Johnson Reports 2020 Fourth-Quarter And Full Year Results
Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. "Our notable full year performance reflects the continued confidence from patients, physicians, . . .
Posted on 1/26/21
VYNE Therapeutics Sale of $50 Million Registered Direct Offering of Common Stock
BRIDGEWATER, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) today announced that it has entered into definitive agreements with institutional and accredited . . .
Posted on 1/26/21
Pacira BioSciences Equity Invest in GeneQuine Biotherapeutics
PARSIPPANY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today announced that the . . .
Posted on 1/26/21
States that Have the Fewest COVID-19 Restrictions – Updated WalletHub Study
With the U.S. starting to open up more but a full reopening only possible once we achieve widespread vaccination, the personal-finance website WalletHub today released updated . . .
Posted on 1/26/21
Why Pfizer's Future Looks Better in 2021
Despite the success of its COVID-19 vaccine program, Pfizer(NYSE:PFE) didn't impress investors with its stock performance last year. That could change going forward, though. In this . . .
Posted on 1/26/21
Merck Gives Up on Coronavirus Vaccines
Pharmaceutical giant Merck (NYSE:MRK) officially threw in the towel on its efforts to develop a COVID-19 vaccine. The company said it's discontinuing the development of two . . .
Posted on 1/26/21
Caladrius Biosciences Closes $25.0 Million Private Placement
BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed . . .
Posted on 1/26/21
OncoSec Medical Closes $42.0 Million Public Offering of Common Stock
OncoSec Medical Incorporated (NASDAQ:ONCS), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and guide an anti-tumor . . .
Posted on 1/26/21
INOVIO Closes Public Offering of Common Stock
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including . . .
Posted on 1/25/21
Citius Pharmaceuticals Announces $20.0 Million Private Placement
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has entered into securities purchase . . .
Posted on 1/25/21
Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine . . .
Posted on 1/25/21
Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update
PRINCETON, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today . . .
Posted on 1/25/21
What Kind of Deals Is Pfizer Planning for the Next Few Years?
Pfizer(NYSE:PFE) has a long and storied history of deal-making. And the big drugmaker's business development activities aren't likely to fall by the wayside in 2021. In . . .
Posted on 1/25/21
Why Pfizer's Future Looks Better in 2021
Despite the success of its COVID-19 vaccine program, Pfizer(NYSE:PFE) didn't impress investors with its stock performance last year. That could change going forward, though. In this . . .
Philadelphia
